Table 6.

Demographic characteristics and functional follow-up parameters of Group 3 (management with WJ-MSC + rEMS combination).

Patient No	Eye	BCVA		FPDI		ERG magnitude
		Time0	Time1	Time0	Time1	Time0	Time1
1	R	70	80	28	30	0.66	0.89
	L	80	85	34	36	0.70	0.91
2	R	100	110	67	71	0.63	0.96
	L	100	110	65	69	0.61	0.96
3	R	50	35	6	4	0.44	0.40
	L	50	40	8	6	0.46	0.42
4	R	85	85	54	52	0.59	0.86
	L	80	80	50	49	0.56	0.84
5	R	75	75	42	42	0.51	0.56
	L	85	85	48	49	0.55	0.61
6	R	50	45	38	37	0.45	0.51
	L	55	50	39	37	0.50	0.56
7	R	65	60	30	28	0.39	0.39
	L	65	60	31	28	0.41	0.40
8	R	75	75	36	36	0.44	0.65
	L	80	80	37	37	0.47	0.68
9	R	65	60	39	37	0.61	0.60
	L	60	55	37	35	0.60	0.58
10	R	75	75	33	33	0.63	0.74
	L	80	80	35	35	0.65	0.78
11	R	50	50	27	27	0.36	0.48
	L	50	50	28	28	0.37	0.50
12	R	80	85	36	37	0.66	0.78
	L	85	85	37	38	0.68	0.79
13	R	100	110	60	62	0.76	0.99
	L	100	110	60	62	0.75	0.98
14	R	60	60	31	31	0.37	0.74
	L	55	55	29	29	0.36	0.75
15	R	35	35	5	5	0.34	0.41
	L	40	40	8	8	0.36	0.44
16	R	110	110	61	61	0.78	0.96
	L	110	110	62	62	0.80	0.98

Time0 (baseline): just before the WJ-MSC and Magnovision application.

Time1: 36th month after injection and 36th month of weekly rEMS sessions.

BCVA, best corrected visual acuity, (ETDRS letters); ERG magnitudes, full field flicker electroretinography magnitudes (mV); FPDI, fundus perimetry deviation index (%); rEMS, repetitive electromagnetic stimulation; WJ-MSCs, Wharton’s jelly derived mesenchymal stem cells.